Category Archives: Dermatology

Dermatology

Enhancing the Patient Experience Through Addressing Pain Points … – Dermatology Times

Joe Cari, MPAS, PA-C, currently practices as a physician assistant in Highlands Ranch, Colorado. Previously, Cari worked in advertising and marketing before making a career pivot and becoming a dermatology PA in 2014.

At the 2023 Society of Dermatology Physician Assistants (SDPA) Annual Fall Dermatology Conference in Nashville, TN, Cari presented a session titled, From The Parking Lot to Check Out: Tips For a Great Patient Experience,1 detailing advice for approaching the patient experience from an advertising, marketing, and health care professional perspective.

These are ways to identify those pain points yourself and maybe make suggestions, or even maybe you can bring it to the higher ups to sort of bring yourself a little bit forward in the leadership conversation, Cari said.

Caris main advice for PAs revolves around what he calls being extra, or going above and beyond in each and every area of the patient journey mapping.

Arrival

Check-in

Cari believes that in the next 5 to 10 years, health care and medicine may see artificial intelligence booming in the latter.

Waiting room

Cari frequently recommended virtual reality availability in clinics and practices as a means to improve the patient experience. This, he said, may represent the future of anxiety relief in patients.

Consultation and treatment

Procedure fear and anxiety

Check out and follow up

The positive patient-centric dermatology experience is what we're all looking for. Identifying pain points along your entire patient journey is going to be very, very important to not only yourself, mitigate those, but correct those deficiencies within the clinic, Cari said. It's going to encourage teamwork and communication with your leadership and among the medical providers and professionals, and its going to help staff enhance patient care and want to change.

Cari referenced a UK patient complaint study wherein almost 70% of all complaints reported by patients have the potential to be addressed or mitigated with a health care professional or a PAs involvement and carefulness. 22.1% of complaints were related to treatment, 16.8% to communication, 15% to skills and conduct, and 13.9% to respect. Perceived experiences, Cari said, make up the largest proportion of patient complaints and concerns in a practice.

If you choose to listen, to change, it not only helps you and your understanding of the patient's perspective, but also your understanding and perspective, which makes for a better patient experience, better patient care, and that's going to make you a better provider, Cari said.

Reference

Originally posted here:

Enhancing the Patient Experience Through Addressing Pain Points ... - Dermatology Times

Dermatology

Global Dermatology Collaboration and Licensing Deals and Agreements Analysis Report 2023 with Directory of Dermatology Deal Records Signed Since 2016…

Global Dermatology Collaboration and Licensing Deals and Agreements Analysis Report 2023 with Directory of Dermatology Deal Records Signed Since 2016  Yahoo Finance

Read the original post:

Global Dermatology Collaboration and Licensing Deals and Agreements Analysis Report 2023 with Directory of Dermatology Deal Records Signed Since 2016...

Dermatology

UNION therapeutics to present at 7th Annual Dermatology Drug … – PR Newswire

HELLERUP, Denmark, Oct. 25, 2023 /PRNewswire/ -- UNION therapeutics A/S (UNION), a privately held, clinical stage, pharmaceutical development company focused on immunology and infectious disease, today announced that Dr. Kim D.Kjller, CEO of UNION therapeutics will present at the seminar on clinical trials at the 7thAnnual Dermatology Drug Development Summit on October 31 - November 2, 2023, in Boston, US.

Dr. Kjller will discuss recent challenges and progress in assessing efficacy in clinical trials of hidradenitis suppurativa (HS) and how novel endpoints may improve the approach. To perspectivize the discussion, data from the OSIRIS, proof-of-concept study of oral orismilast in HS presented at the European Academy of Dermatology and Venerology (EADV) Congress 2023 will be presented.

7thAnnual Dermatology Drug Development Summit

Presentation: Demonstrating efficacy in clinical trials with novel and meaningful endpoints Presenter:Dr. Kim D. Kjller, CEO, UNION therapeutics Date and time:Wednesday November 1, 2023, at 10:40am EST.

Contacts

Morten Boesen, Chief Financial Officer, UNION therapeutics A/S +45 2381 5487 [emailprotected]

Sarah Toft-Jrgensen, Director of Communications and IR, UNION therapeutics A/S +45 5385 3044 [emailprotected]

About UNION therapeutics

UNION therapeutics is a privately held, mid- to late-stage, pharmaceutical development company advancing novel treatment options within immunology and infectious diseases. UNION is headquartered in Hellerup, Denmark, and led by an international team combining biotech entrepreneurs and seasoned pharma executives, with a track record of developing and launching more than fifteen marketed drugs. Read more at http://www.uniontherapeutics.com

SOURCE UNION therapeutics

View original post here:

UNION therapeutics to present at 7th Annual Dermatology Drug ... - PR Newswire

Dermatology

4 Tips and Considerations for Selecting a Systemic Treatment for … – Dermatology Times

/Adobe Stock

At the 2023 Society of Dermatology Physician Assistants (SDPA) Annual Fall Dermatology Conference in Nashville, TN, Douglas DiRuggiero, DMSc, PA-C, presented a session titled, Psoriasis: How to Choose the Best Systemic Treatment for your Patient,1 where he discussed considerations and best practices for determining an appropriate systemic treatment for patients with psoriatic disease.

Make sure you know what you're diagnosing because youll never have the right treatment if you've got the wrong diagnosis, DiRuggiero said. Always put the patient first, because while we have 12 biologicscreams, 2 orals, multiple topicals, and a lot of other treatments: The best treatment for your patient is the thing that fits their needs best.

There are several factors involved in determining an appropriate treatment path for a patient with psoriasis. DiRuggiero notes that these include severity of disease, body surface area, involvement in sensitive areas, pre-existing or comorbid conditions, patient quality of life, and most importantly, patient choice.

Psoriasis by itself is its own black box warning, DiRuggiero said.

DiRuggiero went on to note that for patients with psoriasis, the risk of developing conditions such as fatty liver disease, metabolic syndrome, and cardiac disease, for example, are greater than in patients without psoriasis or psoriatic disease.

Psoriasis is a part of an umbrella known as the psoriasis-associated autoimmunity spectrum. DiRuggiero said that because of this, there is a considerable amount of overlap between cutaneous psoriasis and numerous other autoimmune conditions. For example, approximately 2% to 6% of patients with psoriasis, DiRuggiero noted, will develop irritable bowel disease (IBD). Patients may even have IDB at the time of their diagnosis with psoriasis and not even know it. This background is important to consider when deciding how to best manage or treat a patients psoriasis.

Psoriasis does not present equally in all patients, particularly in patients with skin of color and more darkly-pigmented skin types.

DiRuggiero said that it is important for health care providers to develop differential diagnoses for their patients and to consider that while something may appear to be psoriasis, it does not always make it psoriasis.

Never assume its a slam dunk case, he said.

Shared decision making is a little bit of a difficult venture, DiRuggiero said. I call it controlled decision making.

When a patient comes into a practice with potential drug names in mind that they may have heard of or previously researched, it is important to acknowledge that while the particular treatment may be effective and a great choice for another patient, not every patient is created equally.

I dont think PASI is the thing to drive all decisions, DiRuggiero said.

Instead, he suggests guiding patients through acknowledgment of their input while also ensuring they are aware that a full examination of their medical history may mean their preferred treatment option is not the best fit for them.

[Patients] need to hear that there's hope, that there's positivity to a disease. The fact is that if someone develops liver dysfunction, or liver failure, or develops macular degeneration and becomes blind, to the public, that brings a sense of sympathy and empathy, DiRuggiero said. But when someone develops a disease of the largest organ in the body and its invisible, it doesnt earn sympathy. It brings repulsion.

He went on to describe the present treatment landscape and era for psoriasis as a great time to be living with the condition, simply due to the wide variety of treatment options available for patients and their respective, individualized needs.

I'd never dreamed I have 20 new approved products for psoriasis in my prescribing career, DiRuggiero said. Don't lose the fact that we are prescribing hope, and we have a chance to put on a cape every day and become someone's hero."

Reference

See original here:

4 Tips and Considerations for Selecting a Systemic Treatment for ... - Dermatology Times

Dermatology

Yales Richard Edelson on what got him started in research for … – The Cancer Letter

After graduating from Hamilton College as a chemistry major, Richard Edelson received his MD from the Yale School of Medicine. He then sequentially trained in internal medicine at the University of Chicago, dermatology in the Harvard Program, and cancer immunology at NIH.

Before being recruited back to his alma mater as chairman and professor of the YSM Department of Dermatology in 1986, he was director of the Immunobiology Group in Columbia Universitys Comprehensive Cancer Center, associate director of that institutions General Clinical Research Center, and professor and director of research in Columbias Dermatology Department.

While on the Yale faculty, he served continuously as chairman of the Department of Dermatology (1986-2022), and at overlapping times, has also been the director of the Yale University Comprehensive Cancer Center (2003-2009), YSM deputy dean overseeing all clinical departments (2000-2003), Leader of the YSM Cancer Centers Lymphoma Research Program and the YSM faculty representative to the Yale New Haven Hospital Board of Trustees.

On Oct. 1, 2022, after serving as departmental chairman for 37 years (the longest duration of any Yale University departmental chairman in University history), he resigned the position, while remaining a full-time professor of dermatology.

He was recently announced as the recipient of the first Advanced Research Projects Agency for Health (ARPA-H) grant in the United States, which is an outgrowth of President Bidens Cancer Moonshot program.

The nearly $25 million award, titled Curing the Uncurable via RNA Encoded Immunogene Tuning, aims to train the immune system to better fight cancer and other diseases by educating specific immune cells with mRNA technology. Philip Santangelo, of Emory and Georgia Tech, is the principal investigator, who will provide designer mRNA, and Edelson is a co-principal investigator on the project.

Go here to read the rest:

Yales Richard Edelson on what got him started in research for ... - The Cancer Letter

Dermatology

Cape Henlopen Dermatology Is First in Delaware to Offer … – PR Newswire

BURR RIDGE, Ill., Oct. 25, 2023 /PRNewswire/ -- SkinCure Oncology, the world leader in providing a comprehensive model for the delivery of Image-Guided Superficial Radiation Therapy (Image-Guided SRT), the most advanced nonsurgical treatment for common skin cancer, today announced its availability in Delaware at an event at Cape Henlopen Dermatology in Lewes. This is the first medical practice in the state to offer the GentleCure treatment experience.

Image-Guided SRT is the only treatment for nonmelanoma skin cancer (basal and squamous cell carcinoma) that uses ultrasound imaging to help clinicians direct low-level x-rays to targeted areas of the skin, killing cancer cells without bleeding, pain, surgical scarring or need for reconstructive surgery. A study published in the journal Oncology and Therapy showed that Image-Guided SRT produces a 99.3 percent cure rate for early stage nonmelanoma, making it just as effective as traditional surgical treatment.

Kathryn O'Reilly, M.D., Ph.D., of Cape Henlopen Dermatology, noted, "Some 8,500 Delawareans are expected to be diagnosed with nonmelanoma skin cancer this year alone. It is essential for them to have information on all available treatment options, both surgical and nonsurgical, so they can make informed decisions about their care. Image-Guided SRT is one of the most exciting technological innovations in dermatology today. We call it the GentleCure experience, and we are proud to be the first in Delaware to offer it."

Practice co-owner Mitchell Stickler, M.D., added, "For individuals who are fearful of surgery and for those whose other medical conditions make them poor candidates for Mohs surgery, noninvasive Image-Guided SRT is a much-needed option.As we diagnose over 150 nonmelanoma skin cancers per month here at Cape Henlopen Dermatology, Image-Guided SRT is a very welcome tool to add to our armamentarium against the local skin cancer epidemic. We are pleased to be the first practice to offer this technology in the First State."

Also speaking at the event was Lewes City Councilman Khalil Saliba, who said, "This is a very exciting development for the Town of Lewes and our surrounding communities, and I congratulate Drs. O'Reilly and Stickler for their vision and diligence in introducing this cutting-edge treatment to the state of Delaware. Skin cancer is a constant concern in active communities like Lewes. Our bike trails, beaches, and other outdoor activities increase the risks of sun exposure, so this new treatment is welcome, particularly since Delaware residents will no longer need to travel to other states to access this advanced technology."

"We at SkinCure Oncology are delighted to partner with Cape Henlopen Dermatology to offer this highly effective, noninvasive treatment option for their patients," said Kerwin Brandt, Chief Executive Officer of the Chicago-based company. "Patients everywhere should have the choice of curing their nonmelanoma skin cancer without surgery."

About SkinCure OncologySkinCure Oncology is the world leader in providing a comprehensive model for the delivery of Image-Guided Superficial Radiation Therapy (Image-Guided SRT), the most advanced nonsurgical treatment for common skin cancer. The company partners with quality-focused dermatologists, Mohs surgeons and other physicians to bring cancer center-level radiation therapy treatment to private practices. Presented to patients as the GentleCure experience, Image-Guided SRT is available from some 500 physicians nationwide, with more than 65,000 patients having been treated. Learn more about the company atSkinCureOncology.com, and visitGentleCure.comfor helpful consumer and patient information.

Media Contact:Matt Russell Russell Public Communications 520-232-9840 [emailprotected]

SOURCE SkinCure Oncology

Originally posted here:

Cape Henlopen Dermatology Is First in Delaware to Offer ... - PR Newswire

Dermatology

IDP-126 Gel Led to Improvements in Erythema Among Black … – Dermatology Times

A fixed-dose of clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% (IDP-126) gel was safe, well-tolerated, and efficacious in reducing investigator-assessed erythema in Black patients with acne, according to a poster presented at the 2023 Society of Dermatology Physician Assistants Fall Conference in Nashville, TN.1

According to study authors Callender et al, literature and data describing patient outcomes for patients with skin of color in relation to this fixed-dose combination are limited. It is important, they noted, to be conscientious of minimizing skin irritation in patients with more melanin-rich skin due to risk of pigmentary alterations such as hyperpigmentation and hypopigmentation.

The pooled, post hoc analysis examined and analyzed the results of 2 identical phase 3 studies (NCT04214639; NCT04214652) involving patients ages 9 years and older with moderate to severe acne as defined by a score of 3 or 4 for on the Evaluators Global Severity Score scale.

Patients were randomized using a 2:1 ratio, wherein 2 patients were assigned to once-daily treatment with IDP-126 gel for every 1 patient assigned to treatment with a vehicle control gel. Both patient groups were provided with identical cleansers, lotions, and sunscreens on an as-needed basis.

Of 363 patients in the pooled intent-to-treat population, approximately 14.9% self-identified as Black.

As a result of treatment with IDP-126 gel, patients self-identifying as Black experienced improvements in erythema as assessed by investigators. Despite clinical improvements in erythema, investigators noted that no increases or incidences of hyperpigmentation or hyperpigmentation were evident. Rates of erythema had decreased by more than 10% from baseline to week 12 of treatment.

IDP-126 was deemed both safe and well-tolerated in this patient population, with only mild and moderate treatment-emergent adverse events (TEAE) reported among Black patients in the studies. The most commonly-reported TEAE was application site pain, followed by application site pruritus.

Minimizing irritation is a key goal in managing acne in patients with skin of color, given the higher risk of pigmentary alterations in melanin-rich skin, study authors wrote. Despite the limited number of self-identified Black participants in these phase 3 studies, these post hoc analyses add valuable information to the limited literature describing treatment effects and tolerability of fixed-dose combination acne treatments in Black individuals.

Reference

See more here:

IDP-126 Gel Led to Improvements in Erythema Among Black ... - Dermatology Times

Dermatology

Modified Irritation Study Reveals Tazarotene 0.045% Less Irritating … – Dermatology Times

Tazarotene 0.045% is significantly less irritating than trifarotene 0.005% and numerically less irritating than adapalene 0.3%, according to a poster presented at the 2023 Society of Dermatology Physician Assistants Fall Conference in Nashville, TN.1

Authors of a recent modified cumulative irritation study sought to assess the tolerability of trifarotene versus tazarotene versus adapalene, noting that cutaneous irritation as a result of topical retinoids may limit use and adherence from patientsan important factor given the role they play as a mainstay in the acne treatment armamentarium.

Adult patients with normal upper back skin and Fitzpatrick skin types I-II were enrolled in 2 identical, 12-day irritation patch studies.

In each of the 2 studies, 3 patches were applied to patients backs in a double-blind, randomized fashion. Of the 3 patches, 2 contained active ingredients and 1 contained a control product. Patches were placed on the skin every 2 to 3 days for a total of 5 applications.

In the first study, active ingredient patches contained either 0.1 cc of adapalene 0.3% gel or 0.1 cc of tazarotene 0.045% lotion. In the second study, active ingredient patches contained 0.1 cc of trifarotene 0.005% cream or tazarotene 0.045% lotion.

Upon each patch removal, investigators assessed dermal and other effects using a Likert scale.

In the first study, investigators found that while average differences in dermal effects scores were not of statistical significance, both tazarotene and adapalene were deemed mildly irritating in nature.

In the second study, on average, dermal effects scores were significantly higher in areas tested with trifarotene than with tazarotene as early as the first assessment and patch removal. This average only increased after each removal and examination.

Tazarotene 0.045% lotion was significantly less irritating than trifarotene 0.005% cream. Tazarotene 0.045% lotion was numerically less irritating than adapalene 0.3% gel, one of the best-tolerated topical retinoids," study authors wrote. Tazarotene 0.045% lotion allows for simultaneous, uniform, and rapid delivery of hydrating ingredients along with less than half the concentration of tazarotene versus other commercially available.

Reference

Read more here:

Modified Irritation Study Reveals Tazarotene 0.045% Less Irritating ... - Dermatology Times

Dermatology

Grand Island Dermatology celebrates 20th anniversary – Grand Island Independent

Grand Island Dermatology is commemorating a significant milestone this month as it celebrates its 20th anniversary.

Since its inception in 2003, the clinic provided dermatological care to the community.

Dr. Jennifer H. Alberts founded the practice. She is a key figure in the clinics success and growth over the years.

I have been fortunate to work with a wonderful and dedicated team, Alberts said. We have an amazing group of people at Grand Island Dermatology who strive every day to provide the best experience and care for our patients.

The clinic started with five employees. It currently has almost 45 employees. Dr. Susan Corey joined the staff in 2009.

Grand Island Dermatology celebrated its 20th anniversary earlier this month. Founded with five staff members by Dr. Jennifer Alberts in 2003, the clinic now has two doctors (Dr. Susan Corey came on board in 2009), six physician assistants and more than 35 other staff members.

Along with Alberts and Corey, Grand Island Dermatology has six board-certified physician assistants with more than 60 years of combined dermatology and cosmetic experience. They are Jackie Beaver, Laura Fox, Bobbi Hartman, Christopher Linke, Susan Deitrick Rodgers and Sheila Williams.

We are lucky to work with remarkable physician assistants who provided excellent dermatological care, Alberts said.

As a physician-owned practice, Grand Island Dermatology offers a wide range of services that cater to all aspects of dermatology. From medical treatments for skin, hair and nails, to dermatological surgeries and aesthetic procedures, the clinic ensures patients receive the highest quality of care.

Its doctors said one of the distinguishing factors of Grand Island Dermatology is its commitment to staying ahead of the curve in medical advancements. The clinic is often the first in the region to adopt new procedures and technology, ensuring patients have access to the most effective treatments available.

Whether its addressing acne, chronic skin disorders, skin cancer or cosmetic concerns, Alberts says the clinics dedicated staff is committed to delivering personalized and efficient care to its patients and their families.

The clinics cosmetic offerings include a wide range of procedures such as Botox injections, Juvederm/Restylane/Voluma injections, chemical peels, microdermabrasion, HydraFacials, collagen induction therapy, Coolsculpting, PRP treatments, and sclerotherapy. Its state-of-the-art Sciton and Cutera lasers effectively treat various skin conditions, including hair reduction, leg and facial veins, wrinkles, age spots, freckles, red spots and rosacea.

This year, the clinic added Sylfirm X RF Microneedling to its offerings, which is a minimally invasive advance, microneedling treatment that uses radio frequency to treat a wide range of skin concerns.

Microneedling targets and treats abnormal vessels that can lead to melasma, rosacea, and other skin discolorations.

With its 20th anniversary as a significant milestone, both Alberts and Corey say Grand Island Dermatology continues to provide exceptional care and innovative treatments to patients in Grand Island and the surrounding communities.

Alberts said Grand Island Dermatologys dedication to excellence, commitment to advanced technology, and genuine care for patients have made them a trusted name in dermatology.

Dr. Susan H. Corey (left) and Dr.Jennifer H. Alberts are celebrating the 20th anniversary of Grand Island Dermatology. Alberts founded the clinic in 2003; Corey joined the staff in 2009.

I have enjoyed the last 20 years in Grand Island, Alberts said. It has been an honor to care for the people of the Grand Island and the surrounding community. I am thankful for the support of the providers of mid-Nebraska.

I feel privileged to be a part of this practice and to practice dermatology in Central Nebraska, Corey added.

For more information or to make an appointment, call 308-384-9300 or stop by the clinic at 418 N. Webb Road in Grand Island.

More information about the clinic and its services can be found on its website at gidermatology.com.

Get the latest local business news delivered FREE to your inbox weekly.

Visit link:

Grand Island Dermatology celebrates 20th anniversary - Grand Island Independent